SEC Form 4 · accession 0001225208-17-010054
BOSTON SCIENTIFIC CORP · BSX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin J. Ballinger
Officer — EVP & Pres, Interven Cardio
Period of report
May 17, 2017
Accepted (ET)
May 18, 2017 · 4:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885725
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 3, 2017 | G | 400 | $0.00 | D | 86,230 | D | |
| Common StockF2,F1 | May 17, 2017 | S | 12,776 | $26.0909 | D | 73,454 | D | |
| Common StockF3,F1 | May 17, 2017 | S | 16,088 | $26.1758 | D | 57,366 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
- F2Represents the weighted average sale price. These shares were sold in multiple transactions at $26.09 and $26.10. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $26.17 to $26.181, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.